PMID- 33284871
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201209
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 13
IP  - 11
DP  - 2020
TI  - Personalized warfarin treatment based on the PITX2 single nucleotide polymorphism 
      rs6843082.
PG  - 2831-2839
AB  - OBJECTIVE: To explore the effect of PITX2 gene rs6843082 single nucleotide 
      polymorphism on the efficacy and adverse reactions of warfarin in patients with 
      atrial fibrillation and hypertension, and to provide a theoretical basis for 
      individualized warfarin treatment. METHODS: Data on 97 patients with atrial 
      fibrillation and hypertension treated in our hospital were collected from 
      September, 2018 to December, 2019. PCR and SNP genotyping techniques were used to 
      measure the genotype at the rs6843082 locus (pituitary homeobox 2, PITX2) using 
      DNA from the peripheral blood cells of all patients. We compared the efficacy of 
      warfarin and the incidence of adverse reactions in patients of different 
      genotypes. RESULTS: (1) Among 97 subjects, 58 cases (59.79%), 32 cases (32.99%) 
      and 7 cases (7.22%) of PITX2 (rs6843082) genotypes GG, GA and AA were identified 
      respectively. The G and A allele frequencies were 76.29% and 23.71%, 
      respectively. (2) After all patients took warfarin to achieve the standard, the 
      GA group and AA group's time to achieve the standard was significantly longer 
      than that of the GG group (P<0.05). The difference was not statistically 
      significant among groups (P>0.05). Compared with the GG group, the maintenance 
      dose of the AA group was increased (P<0.05). (3) Compared with the GG and the GA 
      group, the probability of bleeding events was higher in the AA group (P<0.05). 
      (4) There was no difference in left ventricular end diastolic volume (LVEDV) and 
      left ventricular end systolic volume (LVESV) group among GG, GA and AA groups 
      (P>0.05). Compared with the GG group, left ventricular ejection fraction (LVEF) 
      of the AA group was significantly reduced (P<0.05). (5) The mortality rates of 
      the GG, GA, and AA groups were 15.51%, 12.50% and 22.57%, respectively, at the 
      end of 120 d follow-up. CONCLUSION: Our findings show that rs6843082 SNP leads to 
      the warfarin dose response differences that were observed in patients with atrial 
      fibrillation and hypertension. Genotyping patients for rs6843082 before 
      initiating warfarin treatment may optimize the treatment response and reduce 
      bleeding incidence.
CI  - IJCEP Copyright (c) 2020.
FAU - Liu, Tianhua
AU  - Liu T
AD  - Department of Cardiology, Shidong Hospital Shanghai 200000, China.
FAU - Huang, Hongman
AU  - Huang H
AD  - Department of Cardiology, Shidong Hospital Shanghai 200000, China.
FAU - Liu, Xinbing
AU  - Liu X
AD  - Department of Cardiology, Shidong Hospital Shanghai 200000, China.
FAU - Yang, Yuya
AU  - Yang Y
AD  - Department of Cardiology, Shidong Hospital Shanghai 200000, China.
FAU - Mei, Xiang
AU  - Mei X
AD  - Department of Cardiology, Shidong Hospital Shanghai 200000, China.
FAU - Feng, Liuliu
AU  - Feng L
AD  - Department of Cardiology, Shidong Hospital Shanghai 200000, China.
LA  - eng
PT  - Journal Article
DEP - 20201101
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC7716133
OTO - NOTNLM
OT  - PITX2
OT  - single nucleotide polymorphism
OT  - warfarin
COIS- None.
EDAT- 2020/12/08 06:00
MHDA- 2020/12/08 06:01
PMCR- 2020/11/01
CRDT- 2020/12/07 17:11
PHST- 2020/06/20 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/12/07 17:11 [entrez]
PHST- 2020/12/08 06:00 [pubmed]
PHST- 2020/12/08 06:01 [medline]
PHST- 2020/11/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2020 Nov 1;13(11):2831-2839. eCollection 2020.